The Stoller Biomarker Discovery Center, developed in partnership with SCIEX, was created to develop new omics technologies for biomarker research to understand the root cause of diseases such as cancer, cardiovascular disease, and autoimmune diseases. We initially announced our collaboration with the University of Manchester back in October 2015.
Tags
Celebrating customer experience: Insights from SCIEX leaders
Introduction Customer Experience Day (CX Day) is a special occasion for SCIEX, celebrated every first Tuesday in October. It’s a day dedicated to recognizing the incredible value of our customers and the relentless dedication of our associates who strive to make...
Detecting low levels of drugs and their metabolites in hair and nail samples using LC-MS/MS
You probably have heard of testing blood and urine samples for the presence of drugs and their metabolites. But do you know about the benefits of hair and nail analysis? In a recent webinar, Tina Binz, Deputy Head of the Center for Forensic Hair Analysis, University of Zurich, discussed the benefits of developing comprehensive and sensitive LC-MS/MS for the detection of low-level drugs and metabolites in keratinized matrices.
LC-MS system replacement: Are you ready?
Meeting deadlines in a bioanalysis laboratory can be a big challenge. Older, less sensitive and less reliable LC-MS systems make it even more difficult. Even the disruption caused by the installation and validation can be disconcerting and delay decisions. Does this sound familiar?
Questions and answers to help improve your mycotoxin analysis
During a recent webinar I shared method details for mycotoxin analysis on the SCIEX 7500 system. In this blog i will share the Q&A for the submitted questions that we did not have chance to answer during the live webinar.
Guide decisions during cell line development with more information at the intact level
Monitoring product quality attributes (PQAs) throughout monoclonal antibody (mAb) development is vital to ensuring drug safety and efficacy. By adopting orthogonal analytical techniques and integrating new technologies that have the potential to provide more information, it is possible to improve product quality and manufacturing efficiency and make more informed decisions.
Maximize NPS analysis with accurate mass spectrometry
LC-MS/MS is a powerful analytical tool in forensic toxicology testing that can support a variety of testing regimes such as screening, confirmation and quantitative workflows. More specifically, analysis of NPS using LC-MS/MS provides many advantages, including the ability to reliably detect new drugs and their metabolites from a variety of biological matrices.
Metabolite identification and peace of mind
Managing metabolite identification (Met ID) studies is challenging, so what is at the top of your priority list as you plan the year ahead? Ensuring you have the data needed to manage product safety, meeting deadlines, staff recruitment and training, maintaining compliance, capital expenses, or something else?
What has the Echo® MS system done for the pharma industry? (And don’t just take our word for it!)
SCIEX was very proud to have an illustration of the Acoustic Ejection Mass Spectrometry (AEMS) technology that powers the Echo® MS system on the front cover of the Journal of the American Society for Mass Spectrometry in January 2023. The associated article—Ultrahigh-Throughput Intact Protein Analysis with Acoustic Ejection Mass Spectrometry—was co-authored by scientists from SCIEX and Merck.
Methods for OPI electrode cleaning for Echo® MS system electrodes
Depending on the samples you are running on the system, it is possible for the Open Port Interface (OPI) electrode to become dirty or occluded over time. Below are two different cleaning strategies that can help you maintain your Echo® MS system and keep your OPI...
Rescheduling a Schedule I substance, and the Delta-8 controversy
Did you know that in the US, drugs and other chemicals are classified into 5 distinct categories depending on the drug’s acceptable medical use and its potential for abuse or dependency? Drugs federally classified as Schedule I substances by the US Drug Enforcement Administration (DEA) are considered to have the highest potential for abuse and for creating severe psychological and/or physical dependence. In addition to heroin, LSD and MDMA (ecstasy), cannabis is classified as a Schedule I substance in the Controlled Substance Act of 1970, which means it has no approved medical usage.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.